CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatmentBEELEN, K; OPDAM, M; LINN, S. C et al.Breast cancer research and treatment. 2013, Vol 139, Num 3, pp 649-655, issn 0167-6806, 7 p.Article

Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancerJOHNSTON, Stephen R. D; MARTIN, Lesley-Ann; LEARY, Alex et al.Journal of steroid biochemistry and molecular biology. 2007, Vol 106, Num 1-5, pp 180-186, issn 0960-0760, 7 p.Conference Paper

Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies : Breast cancersLICHTNER, Rosemarie B.Biomedicine & pharmacotherapy. 2003, Vol 57, Num 10, pp 447-451, issn 0753-3322, 5 p.Article

Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancerMCCAFFERTY, Marc P. J; MCNEILL, Roisin E; MILLER, Nicola et al.Breast cancer research and treatment. 2009, Vol 116, Num 3, pp 425-432, issn 0167-6806, 8 p.Article

Summary of aromatase inhibitor trials : The past and futureGOSS, Paul; VON EICHEL, Leonie.Journal of steroid biochemistry and molecular biology. 2007, Vol 106, Num 1-5, pp 40-48, issn 0960-0760, 9 p.Conference Paper

c-Myc overexpression and endocrine resistance in breast cancerMCNEIL, Catriona M; SERGIO, C. Marcelo; GARDINER-GARDEN, Margaret et al.Journal of steroid biochemistry and molecular biology. 2006, Vol 102, Num 1-5, pp 147-155, issn 0960-0760, 9 p.Conference Paper

Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancerCIRUELOS GIL, Eva Maria.Cancer treatment reviews. 2014, Vol 40, Num 7, pp 862-871, issn 0305-7372, 10 p.Article

mTOR inhibitors in advanced breast cancer: Ready for prime time?MARTIN, Lesley-Ann; ANDRE, Fabrice; CAMPONE, Mario et al.Cancer treatment reviews. 2013, Vol 39, Num 7, pp 742-752, issn 0305-7372, 11 p.Article

Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cellsHISCOX, Stephen; BARNFATHER, Peter; HAYES, Edd et al.Breast cancer research and treatment. 2011, Vol 125, Num 3, pp 659-669, issn 0167-6806, 11 p.Article

Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growthTOLHURST, Robert S; THOMAS, Ross S; BARRY, Sayka et al.Breast cancer research and treatment. 2011, Vol 128, Num 2, pp 357-368, issn 0167-6806, 12 p.Article

An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibitionMARTIN, L.-A; GHAZOUI, Z; WEIGEL, M. T et al.Steroids. 2011, Vol 76, Num 8, pp 772-776, issn 0039-128X, 5 p.Conference Paper

Resistance to Endocrine Therapy : Are Breast Cancer Stem Cells the Culprits?O'BRIEN, Ciara S; HOWELL, Sacha J; FARNIE, Gillian et al.Journal of mammary gland biology and neoplasia. 2009, Vol 14, Num 1, pp 45-54, issn 1083-3021, 10 p.Article

Aromatase inhibitors : Combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistanceJOHNSTON, Stephen R. D; MARTIN, Lesley-Ann; HEAD, Julia et al.Journal of steroid biochemistry and molecular biology. 2005, Vol 95, Num 1-5, pp 173-181, issn 0960-0760, 9 p.Conference Paper

Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivationSIKORA, Matthew J; STRUMBA, Viktoriya; LIPPMAN, Marc E et al.Breast cancer research and treatment. 2012, Vol 134, Num 3, pp 1027-1039, issn 0167-6806, 13 p.Article

Novel D-erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeuticsANTOON, James W; JIAWANG LIU; PONNAPAKKAM, Adharsh P et al.Cancer chemotherapy and pharmacology. 2010, Vol 65, Num 6, pp 1191-1195, issn 0344-5704, 5 p.Article

Molecular Mechanism and Clinical Implications of Endocrine Therapy Resistance in Breast CancerARPINO, Grazia; DE ANGELIS, Carmine; GIULIANO, Mario et al.Oncology. 2009, Vol 77, pp 23-37, issn 0030-2414, 15 p., SUP1Conference Paper

Overcoming endocrine resistance in breast cancer : are signal transduction inhibitors the answer?BEDARD, Philippe L; FREEDMAN, Orit C; HOWELL, Anthony et al.Breast cancer research and treatment. 2008, Vol 108, Num 3, pp 307-317, issn 0167-6806, 11 p.Article

Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cellsLEWIS-WAMBI, Joan S; CURILIFFE, Heather E; KIM, Helen R et al.European journal of cancer (1990). 2008, Vol 44, Num 12, pp 1770-1779, issn 0959-8049, 10 p.Article

Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: Where are we now and where are we going?FEDELE, Palma; CALVANI, Nicola; MARINO, Antonella et al.Critical reviews in oncology/hematology. 2012, Vol 84, Num 2, pp 243-251, issn 1040-8428, 9 p.Article

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancersNAHTA, Rita; O'REGAN, Ruth M.Breast cancer research and treatment. 2012, Vol 135, Num 1, pp 39-48, issn 0167-6806, 10 p.Article

A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancerMASSARWEH, Suleiman; THAM, Yee L; FUQUA, Suzanne et al.Breast cancer research and treatment. 2011, Vol 129, Num 3, pp 819-827, issn 0167-6806, 9 p.Article

Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGFSANCHEZ, B. C; SUNDQVIST, M; FOHLIN, H et al.European journal of cancer (1990). 2010, Vol 46, Num 9, pp 1580-1587, issn 0959-8049, 8 p.Article

Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer : single centre clinical experience from the compassionate use programmeMLINERITSCH, Brigitte; PSENAK, Oskar; MAYER, Peter et al.Breast cancer research and treatment. 2007, Vol 106, Num 1, pp 105-112, issn 0167-6806, 8 p.Article

FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistanceMILLOUR, J; CONSTANTINIDOU, D; LYKKESFELDT, A. E et al.Oncogene (Basingstoke). 2010, Vol 29, Num 20, pp 2983-2995, issn 0950-9232, 13 p.Article

Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancerROCCA, Andrea; FAROLFI, Alberto; BRAVACCINI, Sara et al.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 3, pp 407-420, issn 1465-6566, 14 p.Article